【摘要】 目的 :测定 2型糖尿病和冠心病患者血浆促酰化蛋白 (ASP)水平 ,探讨血浆ASP与体重指数、血脂的相关关系。方法 :实验分 3组 :正常对照组 47例、糖尿病组 63例、冠心病组 62例 ,记录每例被试对象的年龄、性别、身高、体重、血压 ,并计算体重指数 (BMI)。酶联免疫吸附分析法 (ELISA)检测血浆ASP浓度 ,免疫比浊法检测血脂等生化指标。结果 :①糖尿病组、冠心病组ASP水平明显高于正常对照组 (P <0 0 5 )。②ASP与体重指数、收缩压、舒张压、总胆固醇、甘油三酯、低密度脂蛋白胆固醇、载脂蛋白B10 0呈显著正相关 (分别为r =0 3 2 ,P <0 0 1;r =0 2 4,P <0 0 1;r =0 19,P <0 0 1;r =0 3 5 ,P <0 0 1;r =0 10 ,P <0 0 5 ;r =0 2 9,P <0 0 1;r =0 3 2 ,P <0 0 1)。③多元逐步回归分析 :载脂蛋白B10 0、体重指数、高密度脂蛋白胆固醇和舒张压最终进入方程 ,它们是影响血浆ASP水平的重要因素 ,其中载脂蛋白B10 0的作用最大。结论 :ASP参与了糖尿病和冠心病患者脂质代谢紊乱的发生 ,血浆ASP水平可能作为估价糖尿病患者发生心血管疾病危险性的新指标更多还原

【Abstract】 Objective:To estimate the plasma acylation-stimulating protein(ASP)level in diabetic and coronary heart disease patients,and to investigate the correlation of plasma ASP with body mass index(BMI),low density lipoprotein cholesterol:(LDL-C),high density lipoprotein cholesterol(HDL-C),total cholesterol(TC),triglyceride(TG)and apolipoprotein. Methods:Oen hundred Seventy-two subjects were enrolled in this study,including 63 diabetics,62 coronary heart disease patients and 47 health controls.ELISA technique was employed to determine the plasma ASP concentration. Results:① The levels of plasma ASP were increased significantly in diabetes group and coronary heart disease group compared with the controlgroup(p<0.05).② Plasma ASP was positively correlated with BMI,systolic pressure,diastolic pressure,total cholesterol,triglyceride,LDL-c and ApoB100(r=0.32,p<0.01;r=0.24,p<0.01;r= 0.19,p<0.01;r=0.35,p<0.01;r=0.10,p<0.05;r=0.29,p<0.01;r=0.32,p<0.01 respectively).③Multiple regression analysis was performed for BMI,systolic pressure,TC,TG,HDL-C,LDL-C,ApoB100,and diabetes and coronary heart disease.Factor such as ApoB100,BMI,LDL-C and diastolic pressure exerted an important effect on plasma ASP level,especially ApoB100. Conclusion:Plasma ASP is involved in the development of the disordered lipid metabolism in diabetes and coronary heart disease.ASP can be used as a new indicator for estimating insulin resistance in diabetics.Plasma ASP provides us a new index in predicting the cardiovascular risk for diabetic patients.更多还原